SCHEMBL394172

SCHEMBL394172

N#Cc1ccc([N+](=O)[O-])c(F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 5/20 0.59
TDP1 Q9NUW8 2/20 0.58
ATM Q13315 1/20 0.58
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
KAT2B Q92831 1/20 0.48
MAPT P10636 3/20 0.46
MERTK Q12866 2/20 0.43
ALDH1A1 P00352 1/20 0.43
HIF1A Q16665 1/20 0.43
MAPK1 P28482 1/20 0.42
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41
GRIN2B Q13224 1/20 0.41
GRIN2C Q14957 1/20 0.41
GRIN3A Q8TCU5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29717198 1.00 VCAM1 (0.59) VCAM1TDP1ATMMEN1KMT2A
SCHEMBL352298 0.85 VCAM1 (0.64) VCAM1TDP1ATMMEN1KMT2A
SCHEMBL4477143 0.82 VCAM1 (0.70) VCAM1TDP1MEN1KMT2AKAT2B
SCHEMBL16960229 0.81 TDP1 (0.58) VCAM1TDP1ATMMEN1KMT2A
SCHEMBL29146105 0.80 KMT2A (0.49) MEN1KMT2AKAT2BMAPTALDH1A1
SCHEMBL4385438 0.79 VCAM1 (0.61) VCAM1TDP1KAT2BMAPTMERTK
SCHEMBL20385553 0.79 TDP1 (0.55) VCAM1TDP1ATMMEN1KMT2A
SCHEMBL1068675 0.78 VCAM1 (0.59) VCAM1TDP1MEN1KMT2AKAT2B
SCHEMBL16953147 0.78 VCAM1 (0.59) VCAM1TDP1MEN1KMT2AKAT2B
SCHEMBL1667919 0.78 VCAM1 (0.59) VCAM1TDP1MEN1KMT2AKAT2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117945917-A Preparation method of 3-fluoro-4-nitrobenzoic acid 衢州康鹏化学有限公司 2024-04-30 CN claimed
EP-4739680-A1 SOLID FORMS OF TRPV4 ANTAGONISTS Actio Biosciences, Inc. (US) 2026-05-13 EP disclosed
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LTD (HK) 2026-04-09 US disclosed
US-20260035362-A1 GLP-1R AGONISTS AND USES THEREOF QILU REGOR THERAPEUTICS INC (CN) 2026-02-05 US disclosed
EP-4684837-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE Temple University of the Commonwealth System of Higher Education (US) 2026-01-28 EP disclosed
US-20260015348-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS INC (US) 2026-01-15 US disclosed
US-12497382-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2025-12-16 US disclosed
US-20250353842-A1 BICYCLIC AMINE CDK12 INHIBITORS INCYTE CORP (US) 2025-11-20 US disclosed
US-20250340539-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2025-11-06 US disclosed
US-12458642-B2 Metalloenzyme inhibitor compounds CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2025-11-04 US disclosed
WO-2006136402-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2006-12-28 WO disclosed
WO-2006108103-A1 PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION PHARMACOPEIA, INC. (US) 2006-10-12 WO disclosed
WO-2006074388-A2 TRICYCLIC δ-OPIOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-13 WO disclosed
US-20060148800-A1 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-07-06 US disclosed
US-20060148823-A1 Tricyclic delta-opioid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-06 US disclosed
WO-2006021544-A1 2,4-DI(AMINOPHENYL) PYRIMIDINES AS PLK INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-03-02 WO disclosed
WO-2000073313-A1 NEW TRICYCLIC AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE ASTRAZENECA AB (SE) 2000-12-07 WO disclosed
EP-0758013-B1 Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display NIPPON OIL CO LTD (JP) 2000-10-11 EP disclosed
US-5855971-A Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film NIPPON OIL COMPANY, LIMITED (JP) 1999-01-05 US disclosed
EP-0758013-A1 Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display NIPPON OIL COMPANY, LIMITED (JP) 1997-02-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148823-A1 Tricyclic delta-opioid modulators OPRD1, OPRK1, OPRL1 VCAM1 4227/4885TDP1 3925/4885ATM 4879/4885
US-20260035362-A1 GLP-1R AGONISTS AND USES THEREOF GLP1R, GPR119, IAPP VCAM1 423/4885TDP1 3606/4885ATM 2247/4885
US-12458642-B2 Metalloenzyme inhibitor compounds CYP11B2, CYP11B1, HSD11B2 VCAM1 2459/4885TDP1 2721/4885ATM 4026/4885
US-20260015348-A1 COMPOUNDS AS GLP-1R AGONISTS GLP1R, GIPR, GCGR VCAM1 1869/4885TDP1 3894/4885ATM 4251/4885
US-20250353842-A1 BICYCLIC AMINE CDK12 INHIBITORS CDK12, CDK1, CDK2 VCAM1 4514/4885TDP1 1132/4885ATM 138/4885
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CPN1, TPP1, DPP4 VCAM1 2252/4885TDP1 692/4885ATM 4632/4885
US-20060148800-A1 Pyrimidines as PLK inhibitors PLK2, PLK3, TYMP VCAM1 2850/4885TDP1 170/4885ATM 1524/4885
US-20250340539-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 CLK1, CLK2, CLK3 VCAM1 4383/4885TDP1 410/4885ATM 319/4885
US-12497382-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 VCAM1 1203/4885TDP1 3351/4885ATM 4056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.